Moonlake Immunotherapeutics2025财年第二财季实现净利润-55.22百万美元，同比减少127.52%

市场透视08-11

8月11日，Moonlake Immunotherapeutics（MLTX.US）公布财报，公告显示公司2025财年第二财季净利润为-55.22百万美元，同比减少127.52%；其中营业收入为0.00美元，每股基本收益为-0.87美元。从资产负债表来看，Moonlake Immunotherapeutics（MLTX.US）总负债1.02亿美元，其中短期债务1.55百万美元，资产负债比为4.51...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2558817966?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-11 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2558817966","market":"us","top_or_hot":-1,"title":"Moonlake Immunotherapeutics2025财年第二财季实现净利润-55.22百万美元，同比减少127.52%","media":"市场透视","content":"<div>\n<p>8月11日，Moonlake Immunotherapeutics（MLTX.US）公布财报，公告显示公司2025财年第二财季净利润为-55.22百万美元，同比减少127.52%；其中营业收入为0.00美元，每股基本收益为-0.87美元。从资产负债表来看，Moonlake Immunotherapeutics（MLTX.US）总负债1.02亿美元，其中短期债务1.55百万美元，资产负债比为4.51...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000244a48056d7&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moonlake Immunotherapeutics2025财年第二财季实现净利润-55.22百万美元，同比减少127.52%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMoonlake Immunotherapeutics2025财年第二财季实现净利润-55.22百万美元，同比减少127.52%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-11 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000244a48056d7&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月11日，Moonlake Immunotherapeutics（MLTX.US）公布财报，公告显示公司2025财年第二财季净利润为-55.22百万美元，同比减少127.52%；其中营业收入为0.00美元，每股基本收益为-0.87美元。从资产负债表来看，Moonlake Immunotherapeutics（MLTX.US）总负债1.02亿美元，其中短期债务1.55百万美元，资产负债比为4.51...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000244a48056d7&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MLTX","symbol_name":"MoonLake Immunotherapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000244a48056d7&s=b","article_id":"2558817966","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000244a48056d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2558817966","pubTimestamp":1754841668,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月11日，Moonlake Immunotherapeutics公布财报，公告显示公司2025财年第二财季净利润为-55.22百万美元，同比减少127.52%；其中营业收入为0.00美元，每股基本收益为-0.87美元。从资产负债表来看，Moonlake Immunotherapeutics总负债1.02亿美元，其中短期债务1.55百万美元，资产负债比为4.51，流动比率为0.17。机构评级：截至2025年8月11日，当前有16家机构对Moonlake Immunotherapeutics目标价做出预测，其中目标均价为78.69美元，其中最低目标价为61.00美元，最高目标价为108.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"MLTX":"MoonLake Immunotherapeutics"},"translate_title":"Moonlake Immunotherapeutics achieved net profit of-55.22 million US dollars in the second fiscal quarter of fiscal year 2025, a year-on-year decrease of 127.52%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":0.9},"content_text":"8月11日，Moonlake Immunotherapeutics（MLTX.US）公布财报，公告显示公司2025财年第二财季净利润为-55.22百万美元，同比减少127.52%；其中营业收入为0.00美元，每股基本收益为-0.87美元。从资产负债表来看，Moonlake Immunotherapeutics（MLTX.US）总负债1.02亿美元，其中短期债务1.55百万美元，资产负债比为4.51，流动比率为0.17。机构评级：截至2025年8月11日，当前有16家机构对Moonlake Immunotherapeutics目标价做出预测，其中目标均价为78.69美元，其中最低目标价为61.00美元，最高目标价为108.00美元。公司简介：MoonLake Immunotherapeutics 是一家处于临床阶段的生物技术公司，致力于推进治疗方案以满足炎症性皮肤和关节疾病领域的未满足需求。该公司专注于开发 SLK，这是一种新型的三特异性 IL-17A 和 IL-17F 抑制纳米抗体，根据临床试验中观察到的反应水平，其有潜力在皮肤科和风湿病患者中实现疾病修饰。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2558817966","isCrawlerRequest":true}